engleski

Efficacy of eravacycline on carbapenem resistant Enterobacterales in vitro

The main obstacle in treatment of infections caused by carbapenem-resistant Enterobacterales (CRE) are limited treatment options. The novel antimicrobial agents other than β-lactams with activity not being dependent on β-lactamase class are especially important. Eravacycline (ERV) is the first fully synthetic fluorocycline indicated for the treatment of complicated intra- abdominal infections in adults. Eighty CRE isolates at the University Hospital Centre Zagreb, Croatia were examined for susceptibility to ERV by disk diffusion method and minimal inhibitory concentration (MIC). Total of 54 (54/80 ; 67.5%) isolates were susceptible to ERV with MIC50 of ≤0.5 μg/mL and MIC90 of 4 μg/mL. Susceptibility of OXA- 48 positive isolates was not significantly higher in comparison with NDM positive (P=0, 539) and VIM positive (P=0, 7805) isolates. ERV is possible alternative to novel β-lactamase inhibitor combinations for treatment of CRE infections with antimicrobial susceptibility testing of CRE isolate to ERV in particular patient as condicio sine qua non before administration.

eravacycline ; carbapenem-resistant Enterobacterales (CRE) ; β- lactamases ; carbapenemases ; in vitro susceptibility ; disk diffusion ; minimal inhibitory concentration

nije evidentirano